Morfina Medlink (Morphine Hydrochloride Trihydrate)

Morphine acts on the mu‑opioid receptor pathway to provide analgesia for several high‑intensity pain conditions.

• Severe acute pain: provides rapid relief of intense pain episodes.
• Post‑operative pain: helps control pain after surgical procedures.
• Cancer pain: manages persistent pain associated with malignant disease.
• Chronic severe pain: offers long‑term relief for patients with ongoing severe pain.

• Morphine hydrochloride tri­hydrate binds as an agonist to mu‑opioid receptors in the central nervous system. Activation of these G‑protein‑coupled receptors inhibits adenylate cyclase, reduces calcium influx, and increases potassium efflux, leading to decreased neuronal excitability and diminished transmission of nociceptive signals, resulting in analgesia and sedation.

Morphine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Nausea: feeling of sickness often accompanied by an urge to vomit.
• Constipation: reduced bowel movements and hard stools.
• Drowsiness: increased sleepiness or fatigue.
• Dizziness: sensation of light‑headedness or unsteadiness.
• Itching: pruritus, especially on the face and neck.
• Vomiting: expulsion of stomach contents.

Serious or Rare Side Effects

• Respiratory depression: slowed or shallow breathing that can be life‑threatening.
• Severe hypotension: marked drop in blood pressure.
• Adrenal insufficiency: inadequate cortisol production.
• Seizures: uncontrolled electrical activity in the brain.
• Anaphylaxis: severe allergic reaction with airway compromise.
• Cardiac arrest: sudden loss of heart function.

When using Morphine, clinicians should observe specific safety measures to minimize risk.

• Assess pain level: evaluate severity and type before initiating therapy.
• Monitor respiratory function: watch for signs of depression, especially after dose changes.
• Adjust dose in renal/hepatic impairment: reduce dosage or increase monitoring in patients with organ dysfunction.
• Avoid concomitant CNS depressants: limit use with benzodiazepines, barbiturates, or alcohol.
• Use with caution in elderly: start with lower doses and titrate slowly.
• Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Morphine can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Other opioids: additive respiratory depression and sedation.
• Central nervous system depressants (e.g., benzodiazepines, barbiturates): heightened risk of profound sedation and respiratory failure.
• Monoamine oxidase inhibitors (MAOIs): may precipitate severe hypertension or serotonin syndrome.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce morphine plasma levels.
• Diuretics: can enhance hypotensive effects.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase risk of gastrointestinal bleeding when combined.